Physician profile
Tiffany E Groen
NPI 1609019538
$3,542.95
in general payments reported to CMS, 2019-2025
24 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $107 · 2021: $132 · 2022: $105 · 2023: $568 · 2024: $833 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.62 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $712.27 | 2019-2025 | |
| Novo Nordisk INC | $679.75 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $299.30 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $290.39 | 2019-2025 | Veozah |
| Lilly USA, LLC | $288.48 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $263.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $235.73 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.92 | 2023-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.61 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $60.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $59.70 | 2020-2025 | Airsupra |
| Abbvie INC. | $55.85 | 2025 | |
| Ibsa Pharma INC. | $45.42 | 2022-2025 | Tirosint, Licart, Flector |
| Corcept Therapeutics | $42.74 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $38.30 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $31.80 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $27.30 | 2022 | |
| Viatris Specialty LLC | $26.57 | 2025 | Yupelri |
| Agile Therapeutics, INC. | $23.22 | 2022 | |
| Inspire Medical Systems, INC. | $20.80 | 2025 | Inspire |
| Amneal Pharmaceuticals LLC | $17.77 | 2024 | Unithroid |
| Janssen Pharmaceuticals, INC | $17.73 | 2019 | |
| Glaxosmithkline, LLC. | $15.79 | 2019 | |
| Baxter Healthcare | $13.29 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Groen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.